Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Therapeutic Effects of Berberine in Patients With Type 2 Diabetes
This study has been completed.
Sponsors and Collaborators: Shanghai Jiao Tong University of Medicine
National Institutes of Health (NIH)
Information provided by: Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier: NCT00425009
  Purpose

The purpose of this study is to determine whether berberine is effective in the treatment of type 2 diabetes.


Condition Intervention Phase
Type 2 Diabetes
Drug: Berberine
Drug: Metformin
Phase I
Phase II

MedlinePlus related topics: Diabetes
Drug Information available for: Metformin Metformin hydrochloride Dextrose Lipids Berberine
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Effects of Berberine on Improvement of Glucose and Lipid Metabolism in Patients With Type 2 Diabetes

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Primary Outcome Measures:
  • HbA1c at 13 weeks

Secondary Outcome Measures:
  • Blood glucose at 13 weeks
  • Blood lipids at 13 weeks

Estimated Enrollment: 70
Study Start Date: January 2004
Estimated Study Completion Date: December 2004
Detailed Description:

Type 2 diabetes is health threats worldwide. However, treatment of this disease is limited by availability of effective medicines. All of the existing oral hypoglycemic agents have secondary failure after long term administration. Thus, new oral medicines are needed for long term control of blood glucose in patients with type 2 diabetes. In diabetes care, dietary approaches have drawn more and more attention in the prevention and treatment of hyperglycemia. Generally regarded as safe (GRAS) plants have been widely used for their benefits in antioxidation, anti-inflammation, anticancer, anti-obesity and anti-diabetes. Numerous botanical products such as pigments that include anthocyanins and flavonoids have been consumed or studied for anti-obesity and anti-diabetes. However, most of these botanical products are mixtures of multiple compounds. It is difficult to control their quality in the study or production. Up to now, as a single purified compound, berberine is demonstrated to have hypoglycemic effect in vitro and in vivo. Berberine is the main active component of Coptis chinensis French, which was used for thousands of years in China in the treatment of human diseases including diabetes.

Comparison(s): Effects of berberine compared with metformin in newly diagnosed type 2 diabetic patients.

  Eligibility

Ages Eligible for Study:   25 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of type 2 diabetes
  • HbA1c > 7.0% or FBG > 7.0 mmol/L
  • Stable or worsening glycemic control for at least 3 months

Exclusion Criteria:

  • Liver damage
  • Kidney damage
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00425009

Locations
China
Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, China, 200092
Sponsors and Collaborators
Shanghai Jiao Tong University of Medicine
Investigators
Principal Investigator: Jun Yin, MD, PhD Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
  More Information

Study ID Numbers: XH-2002-Clin4
Study First Received: January 18, 2007
Last Updated: January 18, 2007
ClinicalTrials.gov Identifier: NCT00425009  
Health Authority: China: State Food and Drug Administration

Keywords provided by Shanghai Jiao Tong University School of Medicine:
Berberine
Type 2 diabetes
Treatment

Study placed in the following topic categories:
Metabolic Diseases
Metformin
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on January 16, 2009